Sign in
Taking people in United StatesPhase 2

Tests chemotherapy with blinatumomab for new leukemia in young adults

Tests a chemotherapy plan with blinatumomab in young adults with new ALL.

Key facts

Who runs it
Dana-Farber Cancer Institute
Where
Boston, United StatesSee the site
Trial code
Registry title
ALL Backbone in AYAs
Status
Recruiting
Phase
Phase 2
People taking part
67 people, planned
Started
3 Apr 2026
Expected to end
31 Jul 2035
Type of study
Interventional, 2 groups
Treatments tested
  • Blinatumomab
  • Oncaspar
  • Cyclophosphamide
  • Cytarabine
  • Dexamethasone
  • Doxorubicin Hydrochloride
  • Etoposide
  • Mercaptopurine
  • Methotrexate
  • Vincristine
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 50.99 with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.

Age
18.00 to 50.99 years
Sex
All sexes can join.
Disease stage
Newly diagnosed Philadelphia chromosome-negative B-ALL or T-ALL, confirmed by tests. Needs 25% or more lymphoblasts. B-cell or T-cell lymphoblastic lymphoma, mixed phenotype acute leukemia and leukemia in the brain or spinal fluid (CNS leukemia) can join.
Earlier treatment
Allowed before: corticosteroids, hydroxyurea, all-trans retinoic acid (ATRA), chemotherapy given into the spinal fluid, emergency radiation or leukapheresis, and one earlier chemotherapy cycle.
Biomarker or test result
Must be Philadelphia chromosome-negative. Direct bilirubin below 1.4 mg/dL (total bilirubin below 1.4 mg/dL is also fine).

Main reasons for not taking part

  • Philadelphia chromosome-positive or BCR::ABL1 fusion
  • Mature B-cell (Burkitt's) ALL or acute undifferentiated leukemia
  • Taking another investigational drug for this condition
  • Uncontrolled illness, such as serious infection or heart problems
  • Pregnant, or not willing to use effective birth control

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • 3.1.1Confirmed diagnosis of Philadelphia chromosome-negative acute lymphoblastic leukemia
  • Diagnosis should be made by peripheral blood, bone marrow aspirate, bone marrow biopsy, or tissue biopsy demonstrating ≥25% involvement by lymphoblasts, with flow cytometry or immunohistochemistry confirming B-ALL or T-ALL; o Participants with B-cell and T-cell lymphoblastic lymphoma are eligible regardless of bone marrow involvement Participants with mixed phenotype acute leukemia (MPAL) ARE eligible, if an ALL regimen is felt to be most appropriate treatment
  • Participants with CNS leukemia ARE eligible. 3.1.2 Allowed prior therapy:
  • Corticosteroids, hydroxyurea, all-trans retinoic acid (ATRA)
  • IT chemotherapy
  • Emergent radiation therapy or leukapheresis for life threatening complications
  • One cycle of prior chemotherapy (i.e. an induction cycle given at another institution and participant transfers care for post-induction treatment; OR a participant does not meet eligibility prior to induction but does meet eligibility after remission induction); 3.1.3 Age 18.00 - 50.99 years 3.1.4 Direct bilirubin <1.4 mg/dL (total bilirubin < 1.4 mg/dL is acceptable). 3.1.5 Willingness to use effective means of birth control. The effects of chemotherapy on the developing human fetus are unknown. For this reason and because therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study; 3.1.6 Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Philadelphia chromosome-positive / BCR::ABL1 fusion 3.2.2 Participants with mature B-cell (Burkitt's) ALL. Mature B-cell ALL is defined by the presence of surface immunoglobulin AND any of the following: t(8;14)(q24;q32), t(8;22), t(2;8), or c-myc-gene rearrangement by FISH, PCR or other testing. [FISH/PCR testing for c-myc rearrangements is not required prior to study entry, but it is suggested for participants with surface immunoglobulin expression or L3 morphology]. 3.2.3 Participants with acute undifferentiated leukemia. 3.2.4 Participants receiving any other investigational agent for this condition
  • 3.2.7 Pregnant women are excluded from this study because many of the agents used on this protocol have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these chemotherapy agents, breastfeeding should be discontinued if the mother is enrolled
  • 3.2.5 Uncontrolled intercurrent illness including but not limited to ongoing infection with vital sign instability (hypotension, respiratory insufficiency), life-threatening acute tumor lysis syndrome (e.g., with renal failure), symptomatic congestive heart failure, cardiac arrhythmia, intracranial or other uncontrolled bleeding. Circumstances that may significantly interfere with a participant's ability to safely comply with study procedures, such as attend scheduled study visits, adhere to treatment protocols, or complete study assessments. These include a lack of reliable transportation, unstable housing, or psychiatric illness, but reasonable attempts should be made to overcome these circumstances, including but not limited to identifying sponsor, institutional, or thirdparty financial or social support as well as psychiatric consultation for objective assessment. 3.2.6 Sexually active participants of reproductive potential who have not agreed to use an effective contraceptive method for the duration of study participation are ineligible

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 51 years old?

Where in United States

  • Dana-Farber Cancer InstituteBoston, United StatesContact: Marlise R Luskin, MD, MSCETaking people

About the trial

What the trial wants to find out

The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs).

Read full original descriptionShow less

The names of the study drugs involved in this study are:

* blinatumomab (a type of immunotherapy drug) * cyclophosphamide (a type of chemotherapy drug) * cytarabine (a type of antineoplastic agent) * dexamethasone (a type of synthetic glucocorticoid) * doxorubicin (a type of antineoplastic agent) * etoposide (a type of antineoplastic agent) * mercaptopurine (a type of antineoplastic agent) * methotrexate (a type of chemotherapy drug) * pegaspargase (a type of antineoplastic agent) * vincristine (a type of antineoplastic agent)

The 2 groups in the trial

  • ALL Backbone Regimen for B-CellTreatment being tested

    * Steroid Prophase (3-dy cycle): Dexamethasone \& cytarabine * Induction IA (29-dy cycle): Vincristine, dexamethasone, pegaspargase, doxorubicin, IT chemotherapy * Induction IB (42-dy cycle): Cyclophosphamide, cytarabine, mercaptopurine, IT chemotherapy * Blinatumomab Cycle 1, 2 (42-dy cycles): Blinatumomab, dexamethasone, IT chemotherapy * Consolidation I: * Phase IA (28-dy cycle), Phase IC (21-dy cycle): Vincristine, mercaptopurine, methotrexate, dexamethasone, cytarabine, etoposide, pegaspargase, IT chemotherapy * Blinatumomab Cycle 3 (42-dy cycle): Dexamethasone, Blinatumomab, IT chemotherapy * Consolidation II (21-dy cycles for 30 wks): Vincristine, dexamethasone, mercaptopurine, doxorubicin, methotrexate, pegaspargase, IT chemotherapy * Blinatumomab Cycle 4 (42-dy cycle): Dexamethasone, Blinatumomab, IT chemotherapy * Continuation (21-dy cycles): Vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy * End of treatment visit * Follow up

    Treatment: Blinatumomab, Oncaspar, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Mercaptopurine, and Methotrexate

  • ALL Backbone Regimen for T-CellTreatment being tested

    * Steroid Prophase (3-day cycle): Dexamethasone and cytarabine * Induction IA (29-day cycle): Vincristine, dexamethasone, pegaspargase, doxorubicin, IT chemotherapy * Induction IB (42-day cycle): Cyclophosphamide, cytarabine, mercaptopurine, IT chemotherapy * Consolidation I: * Phase IA (28-day cycle) and Phase IC (21-day cycle): Vincristine, mercaptopurine, methotrexate, dexamethasone, cytarabine, etoposide, pegaspargase, IT chemotherapy * CNS Phase (21-day cycle): Dexamethasone, vincristine, mercaptopurine, pegaspargase, IT chemotherapy * Consolidation II (21-day cycles for 30 weeks): Vincristine, dexamethasone, mercaptopurine, doxorubicin, methotrexate, pegaspargase, IT chemotherapy * Continuation (21-day cycles): Vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy * End of treatment visit * Follow up

    Treatment: Blinatumomab, Oncaspar, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Mercaptopurine, Methotrexate, and Vincristine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Treatment of Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Young Adults (AYAs)
Plain-language title
Tests chemotherapy with blinatumomab for new leukemia in young adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07227584, who can take part
Record updated
17 August 2026